Usefulness and limitation of multiple endoscopic biopsy sampling for epidermal growth factor receptor and c-erbB-2 testing in patients with gastric adenocarcinoma

Japanese Journal of Clinical Oncology

Volumn 35, Issue 6, 2005, Pages 324-331

  Kimura, Mikihiko ^a   Tsuda, Hitoshi ^a   Morita, Daisaku ^a   Shinto, Eiji ^a   Tanimoto, Takao ^a   Ichikura, Takashi ^a   Mochizuki, Hidetaka ^a   Matsubara, Osamu ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

c erbB 2 (HER2); Endoscopic biopsy specimen; Epidermal growth factor receptor; Fluorescence in situ hybridization; Intratumor heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; ENDOSCOPIC BIOPSY; FLUORESCENCE IN SITU HYBRIDIZATION; GASTRECTOMY; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE C ERB; PROTEIN EXPRESSION; RELIABILITY; SAMPLING; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; ADENOCARCINOMA; BIOPSY; BIOSYNTHESIS; GASTROSCOPY; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; STOMACH; STOMACH TUMOR;

ADENOCARCINOMA; BIOPSY; GASTRECTOMY; GASTROSCOPY; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 23844500094     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi089     Document Type: Article

References (21)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
3. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-95.
4. Mezzelani A, Alasio L, Bartoli C, Bonora MG, Pierotti MA, Rilke F, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999;80:519-25.
5. Klijamenko J, Couturier J, Galut M, El-Naggar AK, Maciorowski Z, Padoy E, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer 1999;87:312-8.
6. Herbst RS, Hong WK. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 2002;29:18-30.
7. Bunn PA Jr, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002;29:38-44.
8. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002;29:31-7.
9. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
10. Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991;64:79-83.
11. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, et al. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988;48:137-41.
12. Yoshida K, Tsuda T, Matsumura T, Tsujino T, Hattori T, Ito H, et al. Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas. Virchows Arch B 1989;57: 285-90.
13. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am J Pathol 1997;151:761-8.
14. Shun CT, Wu MS, Lin JT, Chen SY, Wang HP, Lee WJ, et al. Relationship of p53 and c-erbB-2 expression to histopathological features, Helicobacter pylori infection and prognosis in gastric cancer. Hepatogastroenterology 1997;44:604-9.
15. Yonemura Y, Ninomiya I, Ohoyama S, Kimura H, Yamaguchi A, Fushida S, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer 1991;67:2914-8.
16. Kimura M, Tsuda H, Morita D, Ichikura T, Ogata S, Aida S, et al. A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements. Virchows Arch 2004;445: 255-262.
17. Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, et al. Status of c-erbB-2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002;98:833-7.
18. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18: 3651-64.
19. David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, et al. c-erbB-2 expression in primary gastric carcinomas and their metastases. Mod Pathol 1992;5:384-90.
20. Selvarajan S, Bay BH, Choo A, Chuah KL, Sivaswaren CR, Tien SL, et al. Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma. J Histochem Cytochem 2002;50:1693-6.
21. Mitchell MS, Press MF. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Semin Oncol 1999;26:108-16.